Cost of hesitation just flipped: management describes buyers no longer able to wait out the decision
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Question asks: does management describe that buyers have recently lost ability to postpone decision, cost of delay increased, and real behavior showing decisions landing. Need identify if any product where management conveys this. Let's scan transcript. Products: Prolia, Repatha, Aimovig, biosimilars, etc. Need see if management describes buyers' cost of inaction rising recently, forcing decisions. For Aimovig: pent-up demand, patients waiting for years, now launching. But is that "cost of delay" changed? Patients suffering from migraine, pent-up demand. Management says "People suffering from migraine and their physicians have been waiting for years for an effective new therapy and they've reacted very well." That suggests unmet need, but not necessarily recent change in cost of waiting. It's new product availability, not buyer's cost of inaction rising. For Repatha: they lowered price to reduce out-of-pocket costs, abandonment rate high. That's about affordability, not cost of delay. For Prolia: osteoporosis, repeat injections. No. Biosimilars? No. Maybe "KYPROLIS" etc? No. Question specifically asks "THE PEOPLE WHO BUY FROM THE COMPANY HAVE RECENTLY LOST THE ABILITY TO POSTPONE THE DECISION" - management conveys waiting has become more expensive/risky for counterparties. Need see if any statement like "patients can no longer wait" or "physicians are forced to act now" due to something. The transcript has "pent-up demand" for Aimovig. But is that a recent change? The product launch itself creates urgency? No, it's new option. The cost of delay for migraine patients has always been high, not recently changed. Management says "patients have been waiting for years" - that implies they could wait until product available. Now they are buying because product exists, not because waiting became more costly. So NO. Also "we expect prescription activity to moderate and normalize" - not sustained forced decisions. Any other? "We have several such products and you can see the benefit of this in the third quarter where our new and recently launched products had double-digit unit volume growth." Not about cost of delay. "With price under pressure, having innovative products which can deliver volume growth by meeting needs of large numbers of patients is ever more important." No. "Repatha...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
PFIE · Q1 2023 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions now, and showing c...YES Management describes a clear shift where buyers' deferred maintenance and retrofits—previously postponed—have now become urgent due to pent-up demand and catch-up efforts, with recent behavior showing these decisions are being forced now, and the broader market opportunity still largely ahead.
BFIN · Q1 2022 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, and this is already producing business, wit...
HNRG · Q3 2021 → YESThe question is about whether management describes that buyers have recently lost the ability to postpone decisions, making waiting more expensive or risky, forcing buying decisions, and showing curre...